



# MARKET RELEASE

23 September 2010

**CBio Limited**

**TRADING HALT**

The securities of CBio Limited (the "Company") will be placed in pre-open at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in pre-open until the earlier of the commencement of normal trading on Monday, 27 September 2010 or when the announcement is released to the market.

Security Code:           CBZ

Lux Wigneswaran  
**Senior Adviser, Issuers (Sydney)**

For personal use only

23 September 2010

The Manager  
Company Announcements Office  
ASX Limited  
20 Bridge St  
SYDNEY NSW 2000

Dear Sir,

**REQUEST FOR TRADING HALT**

Pursuant to Listing Rule 17.1, CBio Limited request's an immediate trading halt of the company's securities ("ASX: CBZ") pending the release of a material announcement concerning capital raising.

The Company expects to make this announcement before the opening of trade on Monday morning (Sept 27).

The Company is not aware of any reason why the trading halt should not be granted.

For and on behalf of the Board

**BEN GRAHAM**  
Company Secretary

COMPANY & INVESTOR RELATIONS  
Ben Graham  
Company Secretary  
CBio Limited  
T: +61 7 3841 4844  
ben.graham@cbio.com.au

MEDIA LIAISON  
Melanie Farris  
Manager, Corporate Projects  
CBio Limited  
T: +61 449 148 448  
melanie.farris@cbio.com.au

**About CBio**

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll® is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis. It is currently being trialled in phase II clinical trials in patients with rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008.

Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll®.

For personal use only

CBio's Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).

### **About Rheumatoid Arthritis**

Rheumatoid Arthritis is a chronic autoimmune disease, mainly characterised by inflammation of the lining of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The effects of RA are systemic, which means it can affect other organs in the body, and cardiovascular dysfunction in addition to RA is common. RA symptoms can make even the simplest activities – such as opening a jar or taking a walk – difficult to manage. RA has a worldwide distribution with a prevalence of 1 to 2% – which currently equates to approximately 100 million people. Prevalence increases with age, approaching 5% in women over age 55. RA is two to three times more common in women than in men and generally occurs between the ages of 40 and 60, but it can also affect young children and older adults. Currently, there is no cure.

For personal use only